rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Savara, Inc.

SVRA · Nasdaq

Health CareBiotechnologyNot moving yet

SVRA stood above a rising 150-day average in 29 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 17.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$4.6M
Officials’ trades on record
0
Institutions holding
177 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$4.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2
WhoDidSharesTraded
David L. LowranceChief Financial Officersold394,528at $5.6822 Jun 2026filed 22 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders177-2 on the quarter
New · exited26 · 29
Reported value$1.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NEA Management Company, LLCunchanged · filed 14 Aug 202624,471,264$150.7M00.0%
Bain Capital Life Sciences Investors, LLCunchanged · filed 14 Aug 202617,600,621$108.4M00.0%
Venrock Adviser, LLCadded · filed 14 Aug 202614,745,943$90.8M+1,005,568+7.3%
DEERFIELD MANAGEMENT COMPANY, L.P.unchanged · filed 14 Aug 202613,569,000$83.6M00.0%
BlackRock, Inc.added · filed 7 Aug 202612,494,498$77.0M+1,203,313+10.7%
TCG Crossover Management, LLCunchanged · filed 14 Aug 202612,362,205$76.2M00.0%
Frazier Life Sciences Management, L.P.unchanged · filed 14 Aug 20269,720,852$59.9M00.0%
Polar Capital Holdings Plcunchanged · filed 14 Aug 20269,541,786$58.8M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,932,545$48.9M+148,632+1.9%
Nantahala Capital Management, LLCreduced · filed 14 Aug 20266,976,810$43.0M-367,973−5.0%
31 Mar 2023 – 30 Jun 2026
63119175Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Braden C. Parker Company insiderChief Commercial Officer · last 24 Sep 20260 · 0
Robert Matthew Lutz Company insiderChief Fin. & Operating Officer · last 15 Jul 20260 · 0
David L. Lowrance Company insiderChief Financial Officer · last 22 Jun 20263 · 13
Joseph S. McCracken Company insiderDirector · last 16 Feb 20264 · 0
David A. Ramsay Company insiderDirector · last 19 Dec 202565 · 1
Matthew Pauls Company insiderCHIEF EXECUTIVE OFFICER · last 16 Dec 202510 · 2
Anne Erickson Company insiderChief Business Officer · last 14 Dec 20250 · 0
Kathleen R. McCabe Company insiderChief Legal Officer · last 14 Dec 20250 · 0
An van Es-Johansson Company insiderDirector · last 9 Dec 20250 · 0
Nevan C. Elam Company insiderDirector · last 9 Dec 20250 · 1
Richard J. Hawkins Company insiderDirector · last 9 Dec 20251 · 3
Yasmine Wasfi Company insiderChief Medical Officer · last 4 Dec 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-53.0%
Debt to equityFY 2025 · to 31 Dec 20250.15×
Share count trendFY 2025 · to 13 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$33.2M
Free cash flowFY 2025 · to 31 Dec 2025−$101.1M

Analyst forecasts

No analyst forecasts yet.